Tagged: medical device

$15.07 million raised so far by Nico via private placement


www.XDATA.co
XDATA – February 19th 2016
Nico disclosed selling 84% of its $18 million non-brokered equity offering to forty-one investors. The sale started on February 5th according to the document filed at the SEC. Based on the offering’s structure, the company has until February 2017 to raise an extra $2.93 million. The company closed three previous unregistered private placements which raised an estimated $21.68 million.
Nico develops technology for the field of corridor surgery, including Cranial, ENT, Spinal and Otolaryngology where access to the surgical site is limited. The company’s technology and products are designed to progress corridor surgery by creating instruments that allow for access through smaller openings and resection of soft tissue abnormalities. Investors include Rose-Hulman Institute of Technology, River Cities Capital Fund, CHV Capital, Cornelius Private Investments, and Twilight Venture Partners.
The company is headquartered in Indianapolis IN. Nico elected to keep its revenues undisclosed.
The executive team includes Jeffrey L Hanthorn, Jim Pearson and Joseph L Mark.
The board of directors includes J Carter McNabb, James R Baumgardt, Keith E Brauer and Niles L Noblitt.

The company has raised an estimated total of $36.76 million via private unregistered security offerings.

Offering recap
Status: First close
Company: Nico
Industry: Other Health Care
Amount offered: $18 million
Amount placed: $15.07 million
SEC filing: Source
First sale: 02-05-2016
Data as of: 02-19-2016
Advertisements

Fractyl Laboratories completed a new equity offering


For more information and other transactions visit www.XDATA.com
XDATA – November 6th 2015
Fractyl Laboratories issued equity for a total of $37.17 million in a non-brokered investment round. The transaction which started on October 23rd, garnered the support of sixteen investors. Two previous unregistered financing rounds raised an estimated $62.98 million.
Fractyl Laboratories develops a minimally invasive, device-based, implant-free duodenal mucosal resurfacing procedure (Revita DMR) that directly addresses the intestinal hormonal impairment that contributes to insulin resistance and changes how the body absorbs and processes sugar. The company is backed by Mithril Capital Management, General Catalyst, Bessemer Venture Partners, and Domain Associates.
The company, led by Harith Rajagopalan, is headquartered in Waltham MA. Fractyl Laboratories elected to keep its revenues undisclosed.
The executive team includes Jay Caplan and Lisa Davidson.
The board of directors includes Ajay Royan, Allan Will, Christopher Gabrieli, Nimesh Shah and Stanley Lapidus.

The company has raised an estimated total of $100.15 million via private unregistered security offerings.

Offering recap
Status: Completed
Company: Fractyl Laboratories
Industry: Other Health Care
Amount offered: $37.17 million
Amount placed: $37.17 million
SEC filing: Source
First sale: 10-23-2015
Data as of: 11-06-2015

Cardionomic reports the successful completion of its equity issuance


XDATA – October 16th 2015
Cardionomic placed $21.83 million worth of securities as part of a non-brokered equity financing round. The placement, which started on October 2nd, lured a total of twelve subscribers. No offering was previously initiated by the company under a registration exemption with the SEC.
Cardionomic develops a neuromodulation therapy for heart failure. The company spun off from Denali Medical II, a New Enterprise Associates (NEA) backed incubator, it is funded by NEA, Greatbatch Medical and Cleveland Clinic Foundation.
The company, headquartered in Forest Lake MN, is led by Steve Goedeke (President and CEO). Cardionomic elected to keep its revenues undisclosed.
The board of directors includes Ali Behbahani, Dan Kaiser, Jay Graf, Karen Shanahan, Michael Demane and William Abraham.
Offering recap
Status: Completed
Company: Cardionomic
Industry: Other Health Care
Amount offered: $21.83 million
Amount placed: $21.83 million
SEC filing: Source
First sale: 10-02-2015
Data as of: 10-16-2015

 

Hey if you didn’t know about it, maybe it is time to add XDATA as part of your market monitoring regimen, 14 days free trials are available here.

For more information visit www.XDATA.co

Auris Surgical Robotics reported the completion of a $150 million financing round


XDATA – September 23rd 2015
$150 million was raised by Auris Surgical Robotics following the successful placement and issuance of its unregistered equity securities. A total of twenty-five investors participated to the non-brokered placement which started on September 8th. Two previous unregistered financing rounds raised an estimated $35.38 million.
Auris Surgical Robotics develops a dual-arm micro-surgical system for ophthalmic surgery. The company is backed by Mithril Capital, Highland Capital Partners, and Lux Capital.
The company is headquartered in San Carlos CA. Auris Surgical Robotics elected to keep its revenues undisclosed.
The executive team includes David Styka and Frederic Moll.
The board of directors includes Aja Royan, Bijan Salehizadeh and Peter Hebert.

The company has raised an estimated total of $184.93 million via private unregistered security offerings.

Offering recap
Status: Completed
Company: Auris Surgical Robotics
Industry: Other Technology
Amount offered: $150 million
Amount placed: $149.55 million
SEC filing: Source
First sale: 09-08-2015
Data as of: 09-23-2015

 

Hey if you didn’t know about it, maybe it is time to add XDATA as part of your market monitoring regimen, 14 days free trials are available here.

For more information visit www.XDATA.co

NxThera unveils $8 million unregistered mezzanine placement

Telcare reports first close at $34.71 million on its mezzanine offering


telcare Telcare placed 95% of its non-brokered mezzanine financing with seven backers. The company launched the offering to raise $36.71 million, so far investors started to subscribe to $34.71 million on October 3rd. The company closed four previous unregistered private placements which raised an estimated $50.04 million.

Telcare develops and markets an FDA-cleared wireless glucose monitoring system. The company uses cellular technology and social networking to bridge the last mile between patients with diabetes, their caregivers, and their families in order to transform the care of chronic illness. Investors include Sequoia Capital, Norwest Venture Partners, and Qualcomm Life Fund.

The company is headquartered in Bethesda MD. Telcare kept its revenues undisclosed.
The executive team includes Andrew Flanagan, John R Dwyer and Jonathan C Javitt.
The board of directors includes Casper De Clercq, Kenneth Melani, Patrick Flynn and Scott Carter.

The company has raised an estimated total of $84.75 million via private unregistered security offerings.

Offering recap
Status: First close
Company: Telcare
Industry: Other Health Care
Amount offered: $36.71 million
Amount placed: $34.71 million
First sale: 10-03-2014
Data as of: 10-20-2014

For more information visit www.XDATA.co

Procellera reported raising $5 million via private placement


vomaris Procellera successfully completed a $5 million non-brokered equity financing round. A total of eight investors started to subscribe to the round one month ago. Two previous unregistered financing rounds raised an estimated $10 million.

The company is a regenerative medical device organization specializing in the bioelectrical field, generating innovative technologies for the wound care market. FDA cleared, its Procellera wound dressing is a wireless, self-contained antimicrobial wound dressing that generates a sustained electrical microcurrent at its surface when activated with a conductive fluid.

The company, headquartered in Tempe AZ, is led by Michael Nagel (CEO). Revenues on or below $1 million were reported by Procellera.
The executive team includes Jeff Stevens, Jeffry Skiba, Mary Maijer, Michel Tanguay, Paul Foster, Sandra Mendez and Scott Weaver.
The board of directors includes Eugene Schneller.

The company has raised an estimated total of $15 million via private unregistered security offerings.

Procellera is registered under the name Vomaris Innovations

Offering recap
Status: Completed
Company: Procellera
Industry: Other Health Care
Amount offered: $5 million
Amount placed: $5 million
First sale: 09-12-2014
Data as of: 10-20-2014

For more information visit www.XDATA.co

Senseonics files for first close after raising 42%


senseonicsSenseonics‘s first close reached $9.94 million. The company’s $23.6 million non-brokered equity issue was 42% sold to eleven investors. The first commitments were received almost two weeks ago. The offering will remain open until May 2015 while an additional $13.66 million worth of securities is sold to investors. The company closed three previous unregistered private placements which raised an estimated $115.56 million. The company is backed by Abingworth Management ltd., Anthem Capital, Delphi Ventures, Greenspring Associates, HealthCare Ventures, NEA and Rho Capital Partners.

Senseonics develops and manufactures a glucose monitoring solution. The solution encompasses a subcutaneous sensor implant that measures glucose in the interstitial fluid for up to six months, a wireless transmitter that activate and receives data from the sensor, and finally a smartphone application (app) to read the data in real-time.

The company, headquartered in Germantown MD, is led by Timothy T Goodnow (President and CEO). Senseonics elected to keep its revenues undisclosed.
The board of directors includes Douglas A Roeder, Ed Fiorentino, Francis H Zenie, John W Littlechild, M James Barrett, Peter Justin Klein and Stephen P Defalco.

The company has raised an estimated total of $125.49 million via private unregistered security offerings.

Offering recap
Status: First close
Company: Senseonics
Industry: Biotechnology
Amount offered: $23.6 million
Amount placed: $9.94 million
First sale: 05-21-2014
Data as of: 05-30-2014

Subscriptions to Cardinal Spine’s equity issue increased


Change: offered +0% / raised +5% / placed 40%

Cardinal Spine reported in a document filed with the SEC that its $1.25 million equity offering is 40% subscribed as of May 30th 2014. Prior investors ponied up an additional $25,000. They had previously subscribed to $475,000 in securities according to another filing disclosed a few days ago. So far, twelve backers committed $500,000 to Cardinal Spine’s offering. The offering is structured as indefinite and will remain open until fully subscribed.

Cardinal Spine commercializes and designs a patented spinal implant and its method of use. The device is designed to optimize the post-surgical environment for enhanced fusion of the bone.

The company is headquartered in Louisville KY. Cardinal Spine disclosed having revenues on or below $1 million.
The executive team includes Frank P Castro.

Offering recap
Status: Intermediary close
Company: Cardinal Spine
Industry: Other Health Care
Amount offered: $1.25 million
Amount placed: $500,000
First sale: 06-27-2013
Data as of: 05-30-2014

Subscriptions to Cardinal Spine’s equity issue increased


Change: offered +0% / raised +6% / placed 36%

Cardinal Spine reported in a document filed with the SEC that its $1.25 million equity offering is 36% subscribed as of May 9th 2014. Prior investors ponied up an additional $25,000. They had previously subscribed to $425,000 in securities according to another filing disclosed a few days ago. So far, eleven backers committed $450,000 to Cardinal Spine’s offering. The offering is structured as indefinite and will remain open until fully subscribed.

Cardinal Spine commercializes and designs a patented spinal implant and its method of use. The device is designed to optimize the post-surgical environment for enhanced fusion of the bone.

The company is headquartered in Louisville KY. Cardinal Spine disclosed having revenues on or below $1 million.
The executive team includes Frank P Castro.

Offering recap
Status: Intermediary close
Company: Cardinal Spine
Industry: Other Health Care
Amount offered: $1.25 million
Amount placed: $450,000
First sale: 06-27-2013
Data as of: 05-09-2014